<DOC>
	<DOCNO>NCT01876082</DOCNO>
	<brief_summary>Desmoids tumor benign soft tissue tumor characterize aggressiveness potential local recurrence . There female predominance sex ratio 2/1 median age diagnosis 30 year . Only complete surgical excision recommend desmoids tumor . Some form desmoid tumor recurrent and/or symptomatic accessible conservative surgical treatment . In clinical situation , medical treatment may achieve tumor control quality life maintenance . Place systemic treatment management desmoids tumor poorly evaluate . Regarding chemotherapy , methotrexate vinblastine protocol actually best evaluated combination , allow observe objective response rate 40 75 % . Toxicity mainly mark risk haematological toxicity . Pazopanib inhibitor multi-target tyrosine kinase , oral form , selective type receptor -1 , -2 -3 VEGF receptor PDGFA B , c-Kit . It currently clinical development human treatment several tumor type .</brief_summary>
	<brief_title>PAZOPANIB Efficacy Tolerance Desmoids Tumors</brief_title>
	<detailed_description>This Phase II , randomize , multicenter , open label trial , evaluate efficacy safety pazopanib versus chemotherapy protocol combine methotrexate vinblastine progressive symptomatic desmoid tumor . This study include 72 patient 15 center French Sarcoma Group . Patients treat accord therapeutic strategy allocate randomization document RECIST progression maximum 12 month : - Arm A = experimental strategy : daily oral administration pazopanib . - Arm B = reference strategy : methotrexate-vinblastine . In case document radiological progression ( RECIST criterion ) : - Patients initially include arm A opportunity , determine investigator , receive arm B treatment , leave study , - Patients initially include arm B opportunity , determine investigator , receive arm A treatment , leave study .</detailed_description>
	<mesh_term>Fibromatosis , Aggressive</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Written consent ; 2 . Age ≥ 18 year ; 3 . ECOG ≤ 1 ; 4 . Histologically confirm desmoid tumor ; 5 . Disease progression patient 's inclusion : completion two similar imaging obtain within 6 month apart ( tolerance 6 week accept ) 6 . Measurable target lesion ( RECIST criterion ) ; 7 . Left ventricular ejection fraction ( MUGA ECHO ) within normal ; 8 . Normal hematological , renal liver function : 1 . Hemoglobin ≥ 9 g / dl ; neutrophil ≥ 1.5 x 109 / l ; platelet ≥ 100 x 109 / l ; prothrombin time INR1 ≤ 1.2 ULN activate partial thromboplastin time ≤ 1.2 ULN ; 2 . Amino alanine transferase aspartate amino transferase ≤ 2.5 ULN ; 3 . Total bilirubin ≤ 1.5 ULN ; 4 . Creatinine ≤ 1.5 mg/dl , creatinine &gt; 1.5 mg/dl , Creatinine clearance ≥ 50 m/min ; 5 . Urinary protein / urinary creatinine ( Pu / Cu ) &lt; 1 . If PU/Cu ≥ 1 , patient must proteinuria 1g/24 h 9 . Women eligible provide : 1 . Physiologically incapable childbearing ( hysterectomy , oophorectomy , bilateral tubal ligation , menopause ) . 2 . Of childbearing age negative pregnancy test week first dose treatment . 3 . Women childbearing potential men must agree take adequate method contraception . Permitted contraceptive method : IUD document failure rate 1 % per year , Partner 's vasectomy , complete sex abstinence ( 14 day inclusion , test period cessation treatment accord chemotherapy described ) , dual contraception , oral contraceptive . Effective contraception must implement : Up 6 month treatment vinblastine Up 5 month treatment Methotrexate men 3 month treatment Methotrexate woman For duration treatment Pazopanib ; 10 . Affiliated social security system 1 . Personal history malignancy except : 1 . Cervical intraepithelial neoplasia ; 2 . Skin basal cell carcinoma ; 3 . Treated localized prostate carcinoma PSA &lt; 1 ; 4 . Neoplasia treat curative intent , remission least five year consider low risk relapse . 2 . Pretreatement Pazopanib Methotrexate vinblastine ; 3 . Known allergy Pazopanib , Methotrexate vinblastine ; 4 . Histological sample available review biological study ; 5 . Clinical abnormality may increase risk gastric bleeding ( exhaustive list ) ; 1 . Gastric tumor know risk bleeding ; 2 . Inflammatory bowel disease gastrointestinal disease may increase risk gastric perforation . 6 . Pathologies lead impaired intestinal absorption ( exhaustive ) : 1 . Malabsorption ; 2 . Major resection small intestine stomach . 7 . Active uncontrolled infectious disease ; 8 . Corrected QT interval &gt; 480 m ; 9 . History cardiovascular disease last 6 month : 1 . Cardiac angioplasty ; 2 . Myocardial infarction ; 3 . Unstable angina ; 4 . Bypass surgery ; 5 . Symptomatic arterial disease . 10 . Congestive heart failure grade II , III IV accord New York Hearth Association ( NYHA ) classification ; 11 . Uncontrolled arterial hypertension ( systolic blood pressure ≥ 140 mmHg diastolic blood pressure ≥ 90 mmHg ) ; 12 . History stroke transient ischemic attack , pulmonary embolism deep vein thrombosis treat , within 6 month ; 13 . History major surgery trauma within 28 day prior first day treatment , presence wound , fracture nonhealed ulcer ; 14 . Evidence active bleeding bleeding tendency ; 15 . Known endobronchial lesion / infiltrative lesion large vessel lung ; 16 . History hemoptysis 2.5 ml eight week precede first day chemotherapy ; 17 . Pulmonary dysfunction , asthma , emphysema , chronic obstructive pulmonary bronchitis , pneumonia , pneumothorax , pulmonary contusion , hemothorax , distress acute respiratory syndrome , pulmonary fibrosis ; 18 . Severe renal dysfunction ; 19 . Severe hepatic dysfunction ; 20 . History psoriasis , rheumatoid arthritis , alcoholism , illness chronic liver dysfunction ; 21 . Any preexist severe unstable medical psychiatric condition , condition may interfere patient safety , collection inform consent adherence treatment ; 22 . Patient refuse could stop take banned drug least 14 day ( 5 halflives drug ) first day start chemotherapy duration study ; 23 . During cancer treatment : 1 . Radiotherapy , surgery tumor embolization within 14 day 1st dose pazobanib ( arm A ) chemotherapy methotrexate , vinblastine ( arm B ) ; 2 . Chemotherapy , immunotherapy , biological treatment , experimental hormone therapy within 14 day 5 halflives medication first day pazopanib ( arm A ) chemotherapy methotrexate , vinblastine ( arm B ) . 24 . History cancer treatment toxicity &gt; grade 1 / whose intensity increase , outside alopecia . 25 . Pregnancy lactation 26 . Concomitant treatment ca n't interrupt replaced indicated methotrexate : 1 . Probenecid ( alone associate sulfamethoxazole ) , 2 . Trimethoprim , 3 . Acetylsalicylic acid ( methotrexate dos 20 mg per week acetylsalicylic acid use dos analgesic antipyretic ( ≥ 500 mg per dose and/or &lt; 3 g per day ) antiinflammatory ( ≥ 1 g per dose / &gt; 3 g per day ) , 4 . Phenylbutazone , 5 . Yellow fever vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Desmoids tumor</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>Phase 2 clinical trial</keyword>
	<keyword>Cross</keyword>
</DOC>